Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-07-01

Clinical Trial Update: Pazopanib and ARQ 197 for Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating pazopanib and ARQ 197 in patients with advanced solid tumors; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ARQ 197 (tivantinib)
  • Pazopanib (Pazopanib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Solid Tumor | Phase 1 | Status: COMPLETED | Results posted: 2022-07-01